BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31985872)

  • 1. Combined anti-CD20 and mTOR inhibition with factor VIII for immune tolerance induction in hemophilia A patients with refractory inhibitors.
    Doshi BS; Raffini LJ; George LA
    J Thromb Haemost; 2020 Apr; 18(4):848-852. PubMed ID: 31985872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin.
    Biswas M; Palaschak B; Kumar SRP; Rana J; Markusic DM
    Front Immunol; 2020; 11():1293. PubMed ID: 32670285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of immune tolerance induction in hemophilia A.
    Schep SJ; Schutgens REG; Fischer K; Boes ML
    Blood Rev; 2018 Jul; 32(4):326-338. PubMed ID: 29482894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin.
    Biswas M; Rogers GL; Sherman A; Byrne BJ; Markusic DM; Jiang H; Herzog RW
    Thromb Haemost; 2017 Jan; 117(1):33-43. PubMed ID: 27683758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B cell-activating factor modulates the factor VIII immune response in hemophilia A.
    Doshi BS; Rana J; Castaman G; Shaheen MA; Kaczmarek R; Butterfield JS; Meeks SL; Leissinger C; Biswas M; Arruda VR
    J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33651716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of tolerance to factor VIII by transient co-administration with rapamycin.
    Moghimi B; Sack BK; Nayak S; Markusic DM; Mah CS; Herzog RW
    J Thromb Haemost; 2011 Aug; 9(8):1524-33. PubMed ID: 21585650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New protocol for immune tolerance induction in acquired hemophilia.
    Nemes L; Pitlik E
    Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of anti-factor VIII antibody levels in patients with haemophilia A receiving immune tolerance induction therapy or bypassing agents.
    Boylan B; Niemeyer GP; Werner B; Miller CH
    Haemophilia; 2021 Jan; 27(1):e40-e50. PubMed ID: 33216433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose immune tolerance induction therapy in children of Arab descent with severe haemophilia A, high inhibitor titres and poor prognostic factors for immune tolerance induction treatment success.
    Elalfy M; Elghamry I; Hassab H; Elalfy O; Andrawes N; El-Ekiaby M
    Haemophilia; 2022 Jan; 28(1):65-72. PubMed ID: 34797008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs.
    Becker-Gotot J; Meissner M; Kotov V; Jurado-Mestre B; Maione A; Pannek A; Albert T; Flores C; Schildberg FA; Gleeson PA; Reipert BM; Oldenburg J; Kurts C
    J Clin Invest; 2022 Nov; 132(22):. PubMed ID: 36107620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD20 as the B-Cell Targeting Agent in a Combined Therapy to Modulate Anti-Factor VIII Immune Responses in Hemophilia a Inhibitor Mice.
    Liu CL; Ye P; Lin J; Butts CL; Miao CH
    Front Immunol; 2014 Jan; 4():502. PubMed ID: 24432019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune tolerance induction in patients with hemophilia A.
    Astermark J
    Thromb Res; 2011 Jan; 127 Suppl 1():S6-9. PubMed ID: 21056905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.
    Chen Y; Luo X; Schroeder JA; Chen J; Baumgartner CK; Hu J; Shi Q
    J Thromb Haemost; 2017 Oct; 15(10):1994-2004. PubMed ID: 28799202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
    Kreuz W; Escuriola Ettingshausen C; Vdovin V; Zozulya N; Plyushch O; Svirin P; Andreeva T; Bubanská E; Campos M; Benedik-Dolničar M; Jiménez-Yuste V; Kitanovski L; Klukowska A; Momot A; Osmulskaya N; Prieto M; Šalek SZ; Velasco F; Pavlova A; Oldenburg J; Knaub S; Jansen M; Belyanskaya L; Walter O; ;
    Haemophilia; 2016 Jan; 22(1):87-95. PubMed ID: 26202305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful immune tolerance induction by FVIII in hemophilia A patients with inhibitor may occur without deletion of FVIII-specific T cells.
    Pautard B; D'Oiron R; Li Thiao Te V; Lavend'homme R; Saint-Remy JM; Peerlinck K; Jacquemin M
    J Thromb Haemost; 2011 Jun; 9(6):1163-70. PubMed ID: 21645224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early eradication of factor VIII inhibitor in patients with congenital hemophilia A by immune tolerance induction with a high dose of immunoglobulin.
    Mizoguchi Y; Furue A; Kagawa R; Chijimatsu I; Tomioka K; Shimomura M; Imanaka Y; Nishimura S; Saito S; Miki M; Ono A; Konishi N; Kawaguchi H; Kobayashi M
    Int J Hematol; 2016 Apr; 103(4):473-7. PubMed ID: 26830966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy.
    Sack BK; Merchant S; Markusic DM; Nathwani AC; Davidoff AM; Byrne BJ; Herzog RW
    PLoS One; 2012; 7(5):e37671. PubMed ID: 22655063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
    Kubisz P; Plamenová I; Hollý P; Stasko J
    Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term tolerance to factor VIII is achieved by administration of interleukin-2/interleukin-2 monoclonal antibody complexes and low dosages of factor VIII.
    Liu CL; Ye P; Lin J; Djukovic D; Miao CH
    J Thromb Haemost; 2014 Jun; 12(6):921-31. PubMed ID: 24684505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemophilia A Inhibitor Subjects Show Unique PBMC Gene Expression Profiles That Include Up-Regulated Innate Immune Modulators.
    Karim AF; Soltis AR; Sukumar G; Königs C; Ewing NP; Dalgard CL; Wilkerson MD; Pratt KP
    Front Immunol; 2020; 11():1219. PubMed ID: 32595650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.